SCHEMBL733005

SCHEMBL733005

Cc1ccccc1-n1c(C(C)Nc2nc(N)nc3[nH]cnc23)nc2cccc(C)c2c1=O

nearest known ligand 0.55

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 18/20 0.55
PIK3R1 P27986 9/20 0.50
PIK3CB P42338 6/20 0.48
PIK3CG P48736 6/20 0.48
PIK3CA P42336 5/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17238765 1.00 PIK3CD (0.55) PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA
SCHEMBL16677159 0.93 PIK3CD (0.57) PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA
SCHEMBL16677823 0.93 PIK3CD (0.57) PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA
SCHEMBL16677774 0.93 PIK3CD (0.54) PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA
SCHEMBL16677816 0.93 PIK3CD (0.54) PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA
SCHEMBL16677836 0.93 PIK3CD (0.57) PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA
SCHEMBL16677157 0.93 PIK3CD (0.54) PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA
SCHEMBL357687 0.91 PIK3CD (0.66) PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA
SCHEMBL357166 0.91 PIK3CD (0.54) PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA
SCHEMBL754923 0.91 PIK3CD (0.56) PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140154772-A1 INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA ICOS CORPORATION (US) 2014-06-05 US claimed
US-8492389-B2 Inhibitors of human phosphatidylinositol 3-kinase delta ICOS CORPORATION (US) 2013-07-23 US claimed
US-20120172591-A1 INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA ICOS CORPORATION (US) 2012-07-05 US claimed
US-8138195-B2 Inhibitors of human phosphatidylinositol 3-kinase delta ICOS CORPORATION (US) 2012-03-20 US claimed
EP-1438052-B1 QUINAZOLIN-4-ONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA ICOS CORP (US) 2010-12-29 EP claimed
US-20100152211-A1 INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA ICOS CORPORATION 2010-06-17 US claimed
US-20080287469-A1 Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation DIACOVO THOMAS G 2008-11-20 US claimed
EP-1885356-A2 PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR INHIBITING LEUKOCYTE ACCUMULATION ICOS CORPORATION (US) 2008-02-13 EP claimed
EP-1755609-A1 METHODS FOR TREATING AND/OR PREVENTING ABERRANT PROLIFERATION OF HEMATOPOIETIC CELLS ICOS CORPORATION (US) 2007-02-28 EP claimed
EP-1750714-A1 PHOSPHOINOSITIDE 3-KINASE DELTA SELECTIVE INHIBITORS FOR INHIBITING ANGIOGENESIS VANDERBILT UNIVERSITY (US) 2007-02-14 EP claimed
US-6949535-B2 for example, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one ICOS CORPORATION (US) 2005-09-27 US claimed
WO-2005067901-A2 METHODS FOR TREATING AND PREVENTING HYPERTENSION AND HYPERTENSION-RELATED DISORDERS MICHIGAN STATE UNIVERSITY (US) 2005-07-28 WO claimed
US-20050054614-A1 Methods of inhibiting leukocyte accumulation NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-03-10 US claimed
US-20050043239-A1 Methods of inhibiting immune responses stimulated by an endogenous factor ICOS CORPORATION 2005-02-24 US claimed
WO-2005016349-A1 METHODS OF INHIBITING LEUKOCYTE ACCUMULATION ICOS CORPORATION (US) 2005-02-24 WO claimed
WO-2005016348-A1 METHOD OF INHIBITING IMMUNE RESPONSES STIMULATED BY AN ENDOGENOUS FACTOR ICOS CORPORATION (US) 2005-02-24 WO claimed
US-20040266780-A1 for example, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one ICOS CORPORATION 2004-12-30 US claimed
EP-1438052-A1 INHIBITORS OF HUMAN PHOSPHATIDYL−INOSITOL 3−KINASE DELTA ICOS CORPORATION (US) 2004-07-21 EP claimed
WO-2003035075-A1 INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA ICOS CORPORATION (US) 2003-05-01 WO claimed
US-20020161014-A1 Purinyl substituted quinazoline-4-one derivatives ICOS CORPORATION, A DELAWARE CORPORATION 2002-10-31 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152211-A1 INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA PIK3CD, PIK3CA, PIK3CG PIK3CD 1/4885PIK3R1 12/4885PIK3CB 4/4885
US-20050054614-A1 Methods of inhibiting leukocyte accumulation PI4KB, PIK3CD, PIK3CA PIK3CD 2/4885PIK3R1 14/4885PIK3CB 4/4885
US-20140154772-A1 INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA PIK3CD, PIK3CA, PIK3CG PIK3CD 1/4885PIK3R1 12/4885PIK3CB 4/4885
US-20020161014-A1 Purinyl substituted quinazoline-4-one derivatives PIK3CD, PIK3CA, PIK3CG PIK3CD 1/4885PIK3R1 18/4885PIK3CB 5/4885
US-20040266780-A1 for example, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one PIK3CD, PIK3CA, PIK3CG PIK3CD 1/4885PIK3R1 7/4885PIK3CB 4/4885
US-20050043239-A1 Methods of inhibiting immune responses stimulated by an endogenous factor PI4KB, PI4KA, PIK3CD PIK3CD 3/4885PIK3R1 46/4885PIK3CB 6/4885
US-20120172591-A1 INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA PIK3CD, PIK3CA, PIK3CG PIK3CD 1/4885PIK3R1 12/4885PIK3CB 4/4885
US-20080287469-A1 Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation PI4KB, PIK3CA, PI4KA PIK3CD 4/4885PIK3R1 23/4885PIK3CB 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.